NDA 212909 · Dr Reddys Labs SA
Biorphen
Phenylephrine Hydrochloride · Intravenous
Last checked: Nov 19, 2026Latest source record: Apr 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Oct 21, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
627
74 Phase 3, 25 recruiting
FAERS reports
3,598
3,445 serious, 1,812 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 31, 2026.
BIORPHEN is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. BIORPHEN injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. ( 1 )
Mechanism: Phenylephrine hydrochloride is an α-1 adrenergic receptor agonist.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 11, 2021 Supplement 1 · Efficacy LabelLetter
- Oct 21, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
- BIORPHEN · PHENYLEPHRINE HYDROCHLORIDE 10MG/ML (10MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
- BIORPHEN · PHENYLEPHRINE HYDROCHLORIDE 0.5MG/5ML (0.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Phenylephrine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac SurgeryPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06802224 · 18,000 participants (planned) · Start Apr 1, 2025 · Primary completion Jul 2028
Drug: Norepinephrine; Phenylephrine · For: Anesthesia; Surgery With General Anesthesia; Noncardiac Surgery and 4 more
Sites: San Francisco, California; College Park, Maryland; Ann Arbor, Michigan · 10 sites in all
- The GUARDIAN Trial - Vasopressor Sub-StudyPivotal-lookingEnrolling by invitation
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT04934748 · 6,254 participants (planned) · Start Jul 25, 2021 · Primary completion Dec 31, 2026
Drug: Phenylephrine; Norepinephrine · For: Blood Pressure
Sites: Omaha, Nebraska; Cleveland, Ohio; Beijing, China · 11 sites in all
- Norepinephrine vs Phenylephrine During General AnesthesiaPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04789330 · 3,626 participants · Start Jul 1, 2021 · Primary completion Apr 1, 2022
Drug: Norepinephrine; Phenylephrine · For: Anesthesia; Surgery; Hypotension
Sites: Los Angeles, California; San Francisco, California · 5 sites in all
- Target Hemodynamics and Brain Injury During General Anesthesia in the ElderlyPivotal-lookingSuspended
Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoAcademic, hospital or other
NCT02428062 · 1,812 participants (planned) · Start Oct 2014 · Primary completion Dec 2018
Drug: Phenylephrine; Intravenous fluids and 4 more · For: Post-operative Cognitive Dysfunction
Sites: Milan, Italy
- OB VEGA-Phenylephrine vs Norepinephrine OutcomesPivotal-lookingNot yet recruiting
Wake Forest University Health SciencesAcademic, hospital or other
NCT07900919 · 1,500 participants (planned) · Start Jan 2027 · Primary completion Dec 2027
Drug: Phenylephrine; Norepinephrine · For: Hypotension During Surgery; Cesarean Birth
Sites: Winston-Salem, North Carolina
- Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac SurgeryPivotal-lookingRecruiting
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT05635227 · 1,200 participants (planned) · Start Nov 10, 2022 · Primary completion Dec 2027
Drug: Dexamethasone phosphate; Isotonic sodium chloride (0.9%) and 2 more · For: Coronary Artery Disease; Aortic Valve Disease
Sites: Copenhagen, Denmark
- Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-GrowthPivotal-lookingNot yet recruiting
Applied Biology, Inc.Industry
NCT06648850 · 1,120 participants (planned) · Start May 1, 2026 · Primary completion Mar 19, 2027
Drug: DA-001; Phenylephrine and 1 more · For: Telogen Effluvium; Female Pattern Hair Loss; Female Pattern Hair Loss, Androgenic Alopecia and 3 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,363
- pemphigus1,074
- joint swelling1,038
- pain1,004
- maternal exposure during pregnancy1,003
- infusion related reaction996
- glossodynia995
- rheumatoid arthritis993
- drug ineffective984
- pericarditis983
- systemic lupus erythematosus981
- wound966
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 14 |
| 2006 | 6 |
| 2007 | 15 |
| 2008 | 15 |
| 2009 | 8 |
| 2010 | 43 |
| 2011 | 18 |
| 2012 | 52 |
| 2013 | 29 |
| 2014 | 16 |
| 2015 | 27 |
| 2016 | 28 |
| 2017 | 46 |
| 2018 | 46 |
| 2019 | 61 |
| 2020 | 109 |
| 2021 | 123 |
| 2022 | 267 |
| 2023 | 318 |
| 2024 | 976 |
| 2025 | 995 |
| 2026 | 384 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Biorphen (Phenylephrine HCL) · HCPCS J2372
2024 spending
$9K
Beneficiaries
1,827
1,849 claims
Per beneficiary
$5
2024 ASP limit $0.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $8,844 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Thymoxamine reverses phenylephrine-induced mydriasis.
Relf SJ, Gharagozloo NZ, Skuta GL, et al. · Am J Ophthalmol 1988 · Clinical Trial, Randomized Controlled Trial
- Norepinephrine versus phenylephrine for treating hypotension during general anaesthesia in adult patients undergoing major noncardiac surgery: a multicentre, open-label, cluster-randomised, crossover, feasibility, and pilot trial.
Legrand M, Kothari R, Fong N, et al. · Br J Anaesth 2023 · Randomized Controlled Trial, Multicenter Study
- Prophylactic norepinephrine or phenylephrine infusion for bradycardia and post-spinal anaesthesia hypotension in patients with preeclampsia during Caesarean delivery: a randomised controlled trial.
Guo L, Qin R, Ren X, et al. · Br J Anaesth 2022 · Letter, Randomized Controlled Trial
- Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial.
Dargent A, Bourredjem A, Jacquier M, et al. · Crit Care Med 2025 · Randomized Controlled Trial, Multicenter Study
- Effect of phenylephrine rescue injection on hypotension after spinal anaesthesia for caesarean delivery when guided by both heart rate and SBP during an early warning window: A randomised controlled trial.
Tang W, Liu H, Zhang Z, et al. · Eur J Anaesthesiol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Reversal of mydriasis by dapiprazole.
Allinson RW, Gerber DS, Bieber S, et al. · Ann Ophthalmol 1990 · Clinical Trial, Randomized Controlled Trial
Sponsor: Dr Reddys Labs SA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.